Mechano growth factor (MGF): research

A muscle-repair peptide idea with mixed lab findings and no human dosing studies.

Also called: MGF, Non-PEG MGF, MGF E peptide, MGF-Ct24E, IGF-1Ec E-domain peptide.

IGF-1 splice variants · Synthetic E-domain peptide associated with IGF-1Ec · Evidence: Animal studies only.

No human administration study found. Human-derived cell work and animal findings are mixed; they do not establish dosing.

Studies

Mechano growth factor (MGF) dosage

Typical reported dose: 100–200 mcg after workouts

  • 100–200 mcg after training: 100–200 mcg, described as bilateral dosing after workouts; days per week not stated, into muscle. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)
  • 100 mcg on four training days: 100 mcg MGF on each listed day monday, Tuesday, Thursday and Friday, into muscle. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)
  • 100 mcg before training: 100 mcg per reported administration before workouts; days per week not stated, into muscle. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)
  • 50 mcg after training, three days: 50 mcg into trained muscles; total across sites is unclear monday, Wednesday and Friday, into muscle. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

Mechano growth factor (MGF) side effects and risks

Reported side effects

  • Injection-site pain, bruising or bleeding: No compound specific human rate. These are injection route risks., moderate. Persistent pain, a growing lump or bleeding needs assessment. (source)
  • Infection or tissue injury from an unregulated injection: No MGF specific rate or denominator was found., serious. Spreading redness, fever or severe pain needs urgent assessment. (source)
  • Allergic or immune reaction: Possible with an injection or its ingredients; no MGF specific human rate., serious. Breathing trouble, swelling or fainting requires emergency care. (source)
  • Blood-sugar changes, theoretical: No direct human evidence for this peptide. Risk is extrapolated from the wider hormone drug setting., serious. Check glucose with symptoms, particularly with insulin or glucose-lowering pills. (source)

Stop and get help if

  • Trouble breathing, throat or tongue swelling, fainting or widespread hives after exposure: Stop exposure and call emergency services immediately. Use prescribed emergency allergy treatment if available.
  • Confusion, seizure, unconsciousness or low blood sugar that does not resolve: Get emergency care. Do not give food or drink to someone who cannot swallow safely.
  • Hot, spreading injection-site redness, fever, pus or rapidly worsening pain: Stop injections and seek urgent medical assessment for infection or tissue injury.
  • Chest pain, severe breathlessness, collapse or new neurological symptoms: Call emergency services now. Tell the team about all peptides and other drugs used.
  • Severe muscle pain or swelling with numbness after a muscle injection: Seek emergency care for possible bleeding or pressure injury in the muscle.

Who should avoid it

  • under18: Precaution: no pediatric dosing or safety study of this synthetic peptide was found.
  • pregnant: Precaution: pregnancy and fetal safety have not been studied.
  • breastfeeding: Precaution: breast-milk transfer and infant effects are unknown.
  • tryingToConceive: Precaution: fertility effects and a safe time to stop before conception are unknown.
  • activeCancer: Precaution: MGF E peptide promoted prostate cancer-cell growth in culture. Human cancer risk has not been measured.
  • cancerHistory: Review prior cancer with the treating clinician. A laboratory cell-growth signal exists; human recurrence risk is unknown.
  • diabetes: Blood-sugar effects are uncharacterized. Insulin and some diabetes pills already raise low-sugar risk.
  • heartCondition: Animal heart findings do not establish human safety. New swelling or breathlessness needs assessment.
  • kidneyDisease: Clearance in kidney disease is unknown. Kidney problems also change blood-sugar and bleeding risks.
  • liverDisease: No dosing adjustment is established. Liver disease can complicate interpretation of IGF-1 tests and bleeding risk.
  • bleedingDisorder: Muscle injections can cause bleeding or a deep collection of blood. This is a route risk, not a proven peptide effect.
  • testedAthlete: WADA 2026 prohibits mechano growth factors at all times under S2.3. PEG modification does not make an analogue permitted.
  • other: Avoid a substance that previously caused a serious allergic reaction. Actual vial ingredients may be uncertain.

Interactions

  • Insulin: Insulin causes low blood sugar. Any added effect of this peptide is untested; symptoms need a glucose check.
  • Sulfonylureas and meglitinides: These pills can cause low blood sugar. No interaction study with MGF or PEG-MGF establishes a safe combination.
  • Growth hormone, IGF-1 and GH-releasing drugs: Stacking adds untested growth and metabolic exposures. Human safety and claims about optimal spacing are unproven.
  • Anticoagulants and antiplatelet drugs: Muscle punctures can bleed or bruise more on these drugs. A direct chemical interaction with the peptide is unknown.
  • PEG-MGF: Related products may be duplicated in a stack. No human study establishes combined exposure or benefit.

Product quality risks

  • Two illicit MGF preparations contained a C-terminal amidated analogue. This small identity study cannot estimate market-wide quality.
  • A separate illicit full-length MGF product contained a modified 12,264.9 Da protein. The MGF name can cover different molecules.
  • Unregulated vials may have the wrong identity or amount, impurities, microbes or bacterial toxins. No compound-specific contamination rate is established.

How Mechano growth factor (MGF) works

The IGF-1 gene can make several versions of a growth protein. MGF products usually contain a short fragment from one version. Some lab studies suggest it changes cell growth or movement, but its receptor and effects remain disputed.

  • MGF E-domain signalling: Some cell studies report growth or movement signals through ERK. An independent study failed to reproduce key effects.
  • IGF-1 receptor: A direct receptor target for the isolated E peptide is not established. It is not interchangeable with mature IGF-1.

Half-life: No human half-life has been established.

Gaps: No human maximum dose exists. aboveStudied is false only because no numeric human comparator is available; it does not imply safety. No label or human trial protocol, independent clinician dosing guideline, or dose-adjustment rule was found. No data establish safety in pregnancy, breastfeeding, conception attempts, children or organ disease. Screening blocks are precautions. Cancer risk, fertility effects, immune reactions and long-term toxicity have not been measured in users. No controlled human study validates stacking, workout timing, microdosing, site-specific growth or cycling breaks. Community frequency tags describe this search, not population prevalence. Copies and plans are not independent use reports. No compound-specific poison-center series or reliable adverse-event denominator was found. National EU approvals and exact UK, Canadian and Australian construct-specific legal coverage need further verification. An FDA enforcement letter mentioning PEG-MGF was located, but seller-identifying titles were excluded from the source set. Human studies of endogenous MGF after exercise or GH, and human cells tested in a dish, are not human MGF administration trials. Synthetic E peptide has not been shown to be interchangeable with the complete IGF-1Ec precursor or a natural circulating hormone. The 2010 review questioned whether the free 24-residue peptide exists naturally. Later cell experiments do not resolve its role in intact humans.

Related to Mechano growth factor (MGF)

Mechano growth factor (MGF): the short version

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.